Axepharma
ActiveSummary
Axepharma has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €310,130 and a net result of €65,629. Equity is growing by about 24% per year across the filed financial years. Its solvency ranks better than 82% of 12,404 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
26-05
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
01-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
31-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Weakest financial yearnet €49,132 ▼29.2%
Net result drops to €49,132, the lowest in the series; recovery starts the following year.
07-08
NBB filing
Annual accounts filed
financial year 2022 · micro format · 7 days late
2022
31-12
Financial
Highest result from 2020 to 2025net €69,445 ▲2.7%
Operating result €113,933, net result €69,445, both a record.
31-12
Financial
Equity above €200,000equity €204,846 ▲51.3%
A profit in every financial year since 2020 builds equity to €204,846.
28-07
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
31-12
Financial
Equity above €100,000equity €135,400 ▲99.7%
A profit in every financial year since 2020 builds equity to €135,400.
22-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.